Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial-Reference-Cited by-同舟云学术

Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial

Published:2024-06 Issue:6 Volume:11 Page:e425-e435
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Aygun Banu,Lane Adam,Smart Luke R,Santos Brígida,Tshilolo Léon,Williams Thomas N,Olupot-Olupot Peter,Stuber Susan E,Tomlinson George,Latham Teresa,Ware Russell E

Funder

Cincinnati Children’s Research Foundation

Wellcome Trust

Kenya Medical Research Institute

National Heart Lung and Blood Institute

Publisher

Elsevier BV

Reference31 articles.

1. Newborn screening for sickle cell diseases in the United States: a review of data spanning 2 decades;Therrell;Semin Perinatol,2015

2. Improved survival of children and adolescents with sickle cell disease;Quinn;Blood,2010

3. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systemic analysis from the Global Burden of Disease Study 2021;Lancet Haematol,2023

4. Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study;Ranque;Lancet Haematol,2022

5. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members;Yawn;JAMA,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa;The Lancet Haematology;2024-06